Lineage Cell Therapeutics, Inc. - Common shares (LCTX)

CUSIP: 53566P109

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Equity / Common shares
Shares outstanding
250,425,788
Total 13F shares
72,831,378
Share change
-1,645,489
Total reported value
$112,314,619
Put/Call ratio
38%
Price per share
$1.54
Number of holders
99
Value change
-$3,915,128
Number of buys
26
Number of sells
55

Quarterly Holders Quick Answers

What is CUSIP 53566P109?
CUSIP 53566P109 identifies LCTX - Lineage Cell Therapeutics, Inc. - Common shares in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q1 2022

As of 31 Mar 2022, Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by 99 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 72,831,378 shares. The largest 10 holders included BROADWOOD CAPITAL INC, BlackRock Inc., VANGUARD GROUP INC, Defender Capital, LLC., GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, Prescott General Partners LLC, JPMORGAN CHASE & CO, RAFFLES ASSOCIATES LP, and NORTHERN TRUST CORP. This page lists 99 institutional shareholders reporting positions in this security for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.